kamuvudine-9
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 29, 2024 (NCT06467435)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human immunodeficiency virusINHIBITOR
Human immunodeficiency virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06781255 | Phase 1 | Mar 13, 2025 | University of Kentucky |
| NCT06467435 | Phase 1 | Aug 29, 2024 | Inflammasome Therapeutics, University of Kentucky |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Kentucky | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Inflammasome Therapeutics | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1